Bibliographic information
Recommendation
We recommend not to use ivermectin in patients with COVID-19 except in the context of a clinical trial
Recommended against
Strong
Certainty of evidence
Very low
Notes and Remarks
Remark This recommendation applies to patients with any disease severity and any duration of symptoms. A recommendation to only use a drug in the setting of clinical trials is appropriate when there is very low certainty evidence and future research has a large potential for reducing uncertainty about the effects of the intervention and for doing so at reasonable cost.
Also Featured In
This recommendation also appears in the following guidelines:
Therapeutics and COVID-19: living guideline, 31 March 2021.
Therapeutics and COVID-19: living guideline, 6 July 2021.
Therapeutics and COVID-19: living guideline, 24 September 2021.
Therapeutics and COVID-19. Living guideline. 7 December 2021
Therapeutics and COVID-19: living guideline, 14 January 2022.
Therapeutics and COVID-19: living guideline, 3 March 2022.
Therapeutics and COVID-19: living guideline, 22 April 2022.
Therapeutics and COVID-19: living guideline, 16 September 2022.
Therapeutics and COVID-19: living guideline, 13 January 2023.